Ariel Fernández Matemático argentino
Fernández, Ariel 1957-
VIAF ID: 122315132 (Personal)
Permalink: http://viaf.org/viaf/122315132
Preferred Forms
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| Folding Cooperativity and the Wrapping of Intermediate States of Soluble Natural Proteins |
|
| From residue matching patterns to protein folding topographies: general model and bovine pancreatic trypsin inhibitor. |
|
| Golden rule for buttressing vulnerable soluble proteins. |
|
| High-Level Quantum Chemistry Empowers the Wrapping Technology for Drug Design |
|
| How do we probe ubiquitin's pathway heterogeneity? |
|
| Human capacitance to dosage imbalance: coping with inefficient selection. |
|
| Hydration profiles of amyloidogenic molecular structures. |
|
| In silico drug profiling of the human kinome based on a molecular marker for cross reactivity. |
|
| Induced disorder in protein-ligand complexes as a drug-design strategy. |
|
| Insufficient hydrogen-bond desolvation and prion-related disease. |
|
| Insufficiently dehydrated hydrogen bonds as determinants of protein interactions |
|
| Intrinsic Fluctuations in Macromolecular Self-Replicating Systems |
|
| Is there a case for selectively promiscuous anticancer drugs? |
|
| Keeping dry and crossing membranes. |
|
| Kinetic assembling of the biologically active secondary structure for CAR, the target sequence for the Rev protein of HIV-1. |
|
| Large-scale context in protein folding: villin headpiece. |
|
| Last Frontier and Back to the Drawing Board: Protein–Water Interfacial Tension in Drug Design |
|
| mathematical approach to protein biophysics |
|
| Membrane thickness cue for cold sensing in a bacterium. |
|
| Modulating drug impact by wrapping target proteins. |
|
| Molecular basis for evolving modularity in the yeast protein interaction network. |
|
| Molecular dimension explored in evolution to promote proteomic complexity |
|
| Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology |
|
| Nanoscale thermodynamics of biological interfacial tension |
|
| Noncoexisting structural elements in catalytic pre-messenger RNA's. |
|
| Nucleation theory for helix unfolding in peptide chains. |
|
| On renormalisation of fluctuations at the onset of a centre manifold |
|
| The onset of macroscopically detectable amplification of template concentration for self-replicating RNA. |
|
| Optical implementation of the generalized Hough transform with totally incoherent light. |
|
| Optical processing of color images with incoherent illumination: orientation-selective edge enhancement using a modified liquid-crystal display. |
|
| Packing defects as selectivity switches for drug-based protein inhibitors |
|
| Packing defects functionalize soluble proteins. |
|
| Partial relaxation of enzyme-product binding by refolding of the growing chain in autocatalytic RNA replication. |
|
| Passive water-lipid peptide translocators with conformational switches: from single-molecule probe to cellular assay. |
|
| Pathway diversity and concertedness in protein folding: an ab-initio approach. |
|
| Pause sites and regulatory role of secondary structure in RNA replication. |
|
| Peptide translocators with engineered dehydration-prone hydrogen bonds. |
|
| Pharmaceutical Industry at the Post-Genomic Junction |
|
| Physics at the biomolecular interface, 2016: |
|
| Prediction of the Sugar Mill Shaft Failure Using a Fracture Mechanics Method |
|
| Preservation of a kinetically originated folding of the cis antirepressor sequence for transport of HIV-1 viral RNA. |
|
| The principle of minimal episteric distortion of the water matrix and its steering role in protein folding. |
|
| Productive induced metastability in allosteric modulation of kinase function. |
|
| Protein Cooperativity and Wrapping: Two Themes in the Transformative Platform of Molecular Targeted Therapy |
|
| Protein packing defects "heat up" interfacial water. |
|
| Protein promiscuity: drug resistance and native functions--HIV-1 case. |
|
| Protein structure protection commits gene expression patterns. |
|
| Protein under-wrapping causes dosage sensitivity and decreases gene duplicability. |
|
| Proteins with H-bond packing defects are highly interactive with lipid bilayers: Implications for amyloidogenesis. |
|
| Provisional theory of nanoscale water dielectrics |
|
| Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. |
|
| Reconstruction of perspective shifts and refocusing of a three-dimensional scene from a multi-focus image stack. |
|
| Redesigning kinase inhibitors to enhance specificity. |
|
| Selective antagonism of anticancer drugs for side-effect removal. |
|
| Selectivity filters to edit out deleterious side effects in kinase inhibitors. |
|
| Self-organisation in the centre manifold of a dissipative system |
|
| Semiempirical Solution to the Protein Folding Problem Through a Combination of Structural and Epistructural Approaches |
|
| Solvent-exposed backbone loosens the hydration shell of soluble folded proteins. |
|
| Statistical mechanical model for proton transfer in RNA |
|
| Statistics of Disordered Polymers: An Effective Hamiltonian and its Associated Gibbs Measure |
|
| Stochastic dynamical constraints in de novo RNA replication. |
|
| Structural defects and the diagnosis of amyloidogenic propensity |
|
| Structure-induced strain determining the internal cyclization site in the yeast cobI5 autocatalytic intron: theory and experimental tests. |
|
| Sub-nanoscale surface ruggedness provides a water-tight seal for exposed regions in soluble protein structure. |
|
| Subfunctionalization reduces the fitness cost of gene duplication in humans by buffering dosage imbalances. |
|
| Supramolecular Evolution of Protein Organization. |
|
| Synergizing immunotherapy with molecular-targeted anticancer treatment. |
|
| Taming the induced folding of drug-targeted kinases. |
|
| Targeted therapy to annihilate the immune-evading phenotype in cancer evolution. |
|
| Theory of scaling for fluctuations in thermal explosion conditions |
|
| Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. |
|
| Time-resolved backbone desolvation and mutational hot spots in folding proteins. |
|
| Topology to geometry in protein folding: beta-lactoglobulin |
|
| Transformative concepts for drug design : target wrapping |
|
| Turning promiscuous kinase inhibitors into safer drugs. |
|
| Under-Wrapped Proteins in the Order–Disorder Twilight: Unraveling the Molecular Etiology of Aberrant Aggregation |
|
| Wrapper Drugs for Personalized Medicine |
|
| Wrapping as a Selectivity Filter for Molecular Targeted Therapy: Preliminary Evidence |
|
| Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer |
|
| Wrapping Deficiencies and De-wetting Patterns in Soluble Proteins: A Blueprint for Drug Design |
|
| Wrapping Drug Combinations for Therapeutic Editing of Side Effects: Systems Biology Meets Wrapping Technology |
|
| Wrapping mimicking in drug-like small molecules disruptive of protein-protein interfaces. |
|
| Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways |
|
| Wrapping technology and the enhancement of specificity in cancer drug treatment. |
|
